CONTEXT: Intensive insulin therapy reduces the risk for long-term complications in patients with type 1 diabetes mellitus (T1DM) but increases the risk for hypoglycemia-associated autonomic failure (HAAF), a syndrome that includes hypoglycemia unawareness and defective glucose counterregulation (reduced epinephrine and glucagon responses to hypoglycemia). OBJECTIVE: The objective of the study was to address mechanisms underlying HAAF, we investigated whether nonglucose fuels such as acetate, a monocarboxylic acid (MCA), can support cerebral energetics during hypoglycemia in T1DM individuals with hypoglycemia unawareness. DESIGN: Magnetic resonance spectroscopy was used to measure brain transport and metabolism of [2-(13)C]acetate under hypoglycemic conditions. SETTING: The study was conducted at the Yale Center for Clinical Investigation Hospital Research Unit, Yale Magnetic Resonance Research Center. PATIENTS AND OTHER PARTICIPANTS: T1DM participants with moderate to severe hypoglycemia unawareness (n = 7), T1DM controls without hypoglycemia unawareness (n = 5), and healthy nondiabetic controls (n = 10) participated in the study. MAIN OUTCOME MEASURE(S): Brain acetate concentrations, (13)C percent enrichment of glutamine and glutamate, and absolute rates of acetate metabolism were measured. RESULTS: Absolute rates of acetate metabolism in the cerebral cortex were 1.5-fold higher among T1DM/unaware participants compared with both control groups during hypoglycemia (P = .001). Epinephrine levels of T1DM/unaware subjects were significantly lower than both control groups (P < .05). Epinephrine levels were inversely correlated with levels of cerebral acetate use across the entire study population (P < .01), suggesting a relationship between up-regulated brain MCA use and HAAF. CONCLUSION: Increased MCA transport and metabolism among T1DM individuals with hypoglycemia unawareness may be a mechanism to supply the brain with nonglucose fuels during episodes of acute hypoglycemia and may contribute to the syndrome of hypoglycemia unawareness, independent of diabetes.
CONTEXT: Intensive insulin therapy reduces the risk for long-term complications in patients with type 1 diabetes mellitus (T1DM) but increases the risk for hypoglycemia-associated autonomic failure (HAAF), a syndrome that includes hypoglycemia unawareness and defective glucose counterregulation (reduced epinephrine and glucagon responses to hypoglycemia). OBJECTIVE: The objective of the study was to address mechanisms underlying HAAF, we investigated whether nonglucose fuels such as acetate, a monocarboxylic acid (MCA), can support cerebral energetics during hypoglycemia in T1DM individuals with hypoglycemia unawareness. DESIGN: Magnetic resonance spectroscopy was used to measure brain transport and metabolism of [2-(13)C]acetate under hypoglycemic conditions. SETTING: The study was conducted at the Yale Center for Clinical Investigation Hospital Research Unit, Yale Magnetic Resonance Research Center. PATIENTS AND OTHER PARTICIPANTS: T1DM participants with moderate to severe hypoglycemia unawareness (n = 7), T1DM controls without hypoglycemia unawareness (n = 5), and healthy nondiabetic controls (n = 10) participated in the study. MAIN OUTCOME MEASURE(S): Brain acetate concentrations, (13)C percent enrichment of glutamine and glutamate, and absolute rates of acetate metabolism were measured. RESULTS: Absolute rates of acetate metabolism in the cerebral cortex were 1.5-fold higher among T1DM/unaware participants compared with both control groups during hypoglycemia (P = .001). Epinephrine levels of T1DM/unaware subjects were significantly lower than both control groups (P < .05). Epinephrine levels were inversely correlated with levels of cerebral acetate use across the entire study population (P < .01), suggesting a relationship between up-regulated brain MCA use and HAAF. CONCLUSION: Increased MCA transport and metabolism among T1DM individuals with hypoglycemia unawareness may be a mechanism to supply the brain with nonglucose fuels during episodes of acute hypoglycemia and may contribute to the syndrome of hypoglycemia unawareness, independent of diabetes.
Authors: Fawzi Boumezbeur; Graeme F Mason; Robin A de Graaf; Kevin L Behar; Gary W Cline; Gerald I Shulman; Douglas L Rothman; Kitt F Petersen Journal: J Cereb Blood Flow Metab Date: 2009-09-30 Impact factor: 6.200
Authors: Douglas L Rothman; Henk M De Feyter; Robin A de Graaf; Graeme F Mason; Kevin L Behar Journal: NMR Biomed Date: 2011-08-31 Impact factor: 4.044
Authors: Kim C C van de Ven; Cees J Tack; Arend Heerschap; Marinette van der Graaf; Bastiaan E de Galan Journal: J Clin Invest Date: 2013-01-09 Impact factor: 14.808
Authors: Fawzi Boumezbeur; Kitt F Petersen; Gary W Cline; Graeme F Mason; Kevin L Behar; Gerald I Shulman; Douglas L Rothman Journal: J Neurosci Date: 2010-10-20 Impact factor: 6.167
Authors: Kim C C van de Ven; Marinette van der Graaf; Cees J Tack; Arend Heerschap; Bastiaan E de Galan Journal: Diabetes Date: 2012-06-11 Impact factor: 9.461
Authors: Kim C C van de Ven; Bastiaan E de Galan; Marinette van der Graaf; Alexander A Shestov; Pierre-Gilles Henry; Cees J J Tack; Arend Heerschap Journal: Diabetes Date: 2011-04-04 Impact factor: 9.461
Authors: Christopher D Morrison; Cristal M Hill; Marina A DuVall; Carolyn E Coulter; Jasmin L Gosey; Matthew J Herrera; Lauren E Maisano; Hunter X Sikaffy; David H McDougal Journal: J Diabetes Complications Date: 2020-02-08 Impact factor: 2.852
Authors: Hanne M M Rooijackers; Evita C Wiegers; Cees J Tack; Marinette van der Graaf; Bastiaan E de Galan Journal: Cell Mol Life Sci Date: 2015-10-31 Impact factor: 9.261
Authors: Evita C Wiegers; Hanne M Rooijackers; Cees J Tack; Bart Wj Philips; Arend Heerschap; Marinette van der Graaf; Bastiaan E de Galan Journal: J Cereb Blood Flow Metab Date: 2018-05-11 Impact factor: 6.200